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The human RON gene (MST1R) maps to 3p21.3, a region frequently altered in lung cancer and other malignancies. It encodes
a receptor tyrosine kinase (RTK) closely related to MET, whose mutations are associated with neoplasia. We investigated
whether RON might be involved in the development or progression of lung cancer. We first determined the exon-intron
structure of the gene by direct sequencing of RON cosmid DNA and PCR products containing intronic sequences, and then
developed primers suitable for mutation analysis by the single-strand conformation polymorphism (SSCP) method. Twenty
coding exons were characterized, all but the first one small (average size: 170 bp), a feature shared with other RTK genes. We
performed SSCP analysis of RON in small and non-small cell lung cancer samples, upon detection of its expression in a sample
of lung cancer cell lines. A mutation (T915C: L296P) was found in an adenocarcinoma specimen. Several single nucleotide
polymorphisms were also found. The panel of intron-anchored primers developed in this work will be useful for mutation
analysis of the RON gene in different types of human tumors. © 2000 Wiley-Liss, Inc.
INTRODUCTION
The human RON gene (MST1R, according to the
official nomenclature, see http://www.ncbi.nlm.nih.
gov/LocusLink/list.cgi) encodes a receptor tyrosine
kinase (RTK) of 1400 amino acids that belongs to the
MET gene family (Ronsin et al., 1993). It is synthe-
sized as a single-chain precursor that undergoes pro-
teolytic cleavage into two single polypeptide chains
linked by disulfide bonds. The mature heterodimeric
protein is composed of one a- (35 kD) and one
b-chain (150 kD). The a-chain is located extracellu-
larly, whereas the b-chain contains an extracellular
portion, a one-pass transmembrane helix, and an in-
tracellular portion that harbors the tyrosine kinase
domain. The number and the location of the disulfide
bonds are still unknown. RON and its ligand, macro-
phage stimulating protein (MSP), are involved in the
development of epithelial tissues, bones, and neuro-
ectodermal tissues, driving cellular proliferation
(Wang et al., 1994; Gaudino et al., 1995; Quantin et
al., 1995). The genes coding for RON and MSP
both map at 3p21.3 (http://www.ncbi.nlm.nih.gov/
genemap/map.cgi?CHR53, Human Genome Map
1998), a region frequently altered in lung, kidney,
and other malignancies (Brauch et al., 1987; Zbar et
al., 1987; Ronsin et al., 1993; Kok et al., 1997). The
predicted amino acid sequences of RON and MET
have overall 33% identity, which increases to 64%
in the kinase domain.
Missense mutations located in the tyrosine ki-
nase domain of the MET gene have been identified
in the constitutional DNA of affected members of
families with hereditary papillary renal cell carci-
noma and in a subset of sporadic renal cell carci-
nomas of the same histology (Schmidt et al.,1997,
1998; Zbar and Lerman, 1998). These are likely to
be gain/change-of-function mutations that lead to
constitutive activation of the MET protein and
tumorigenesis in the renal tissue (Schmidt et al.,
1997, 1998). Similar mutations occurring in other
RTKs are associated with different human malig-
nancies, namely, mastocytomas and gastrointestinal
tumors in the case of KIT (Nagata et al., 1995; Piao
and Bernstein, 1996; Hirota et al., 1998), multiple
endocrine neoplasia types 2A and 2B, and familial
medullary thyroid carcinomas in the case of RET
(Mulligan et al., 1993; Hofstra et al., 1994). Muta-
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tions (D1232V and M1254T) introduced into the
RON kinase domain induce oncogenic and meta-
static properties (Santoro et al., 1998). These mu-
tant RON receptors show an increased kinase cat-
alytic efficiency. Additional findings, both in vivo
and in vitro, suggest that RON could be an onco-
gene. In liver progenitor cells, RON activation has
a strong cell dissociation, motogenic and mitogenic
activity (Medico et al., 1996). In a breast cancer cell
line (ZR75.1), RON activation led to more rapid
proliferation, migration, and invasion (Maggiora et
al., 1998). Rearrangements occurring in the extra-
cellular region of the protein result in altered ki-
nase activity. For example, a RON splicing variant
discovered in a gastric carcinoma cell line (KATO-
III) was found to be responsible for invasive prop-
erties acquired in vitro by these cells (Collesi et al.,
1996). The uncleaved single-chain RON protein
undergoes aberrant intermolecular disulfide dimer-
ization and intracellular oligomerization, and shows
constitutive activation along with the potential of
eliciting a motile-invasive phenotype. The effects
on cell motility shown by the RON/MSP system
were intriguing in view of the high metastatic ac-
tivity of SCLC cells.
To investigate whether the putative proto-onco-
gene RON could contribute to the development or
progression of lung cancer, we first showed that the
gene is expressed in lung cancer cell lines. Next,
we performed mutation analysis of the gene in 55
paired lung cancer samples (Johnson et al., 1988).
RON cDNA was previously cloned (Ronsin et al.,
1993), but the gene exon-intron structure was not
elucidated. To perform a detailed mutation analy-
sis of the RON gene in the lung cancer samples, it
was necessary to define the exon-intron structure
and develop intron-based primers suitable for ex-
onic and splice-site sequence study. We solved the
gene structure through a PCR/sequencing strategy,
and designed intronic primers to apply the single-
strand conformation polymorphism (SSCP) method
to do mutation analysis. We analyzed for mutations
in the kinase-domain exons and the region contain-
ing the protein cleavage site in exon 1.
MATERIALS AND METHODS
Northern Blot Analysis
Filters carrying polyA1 mRNA from several
lung cancer cell lines were prepared according to
Sambrook et al. (1989). Radioactive DNA probes
were prepared by random priming (Rediprime II,
Amersham, Arlington Heights, IL). Hybridization
was performed in ExpressHyb hybridization solu-
tion according to the manufacturer’s instructions
(Clontech Laboratories, Palo Alto, CA).
Determination of the Exon-Intron Structure
To define the exon-intron boundaries of RON,
we designed several PCR primers on the cDNA
sequence (GenBank accession number X70040).
These primers were used on RON cosmid clones
and RON cDNA. Comparing the PCR products by
size allowed us to determine whether an intronic
sequence was present. The sequencing of the PCR
products to identify intronic sequence led to the
characterization of the exon-intron boundaries.
When this approach did not work, because of the
presence of a large intron, we performed direct
primer-walking sequencing on the cosmid DNA.
PCR Reactions
Each PCR primer pair (GIBCO-BRL, Gaithers-
burg, MD; BioServe Ltd, Laurel, MD) was tested
by running the product on a 4% 3:1 Nu-Sieve
agarose gel (FMC, Rockland, ME). All pairs were
used under the following cycling conditions: 1 min
at 95°C, 30 sec at 64°C, 30 sec at 72°C, for 35
cycles. PCR products were cloned using a TA
Cloning Kit (Invitrogen, Carlsbad, CA).
Sequencing
Sequencing reactions were done either manu-
ally (T7 Sequence Kit, Amersham, Arlington
Heights, IL) or automatically (ABI 373 Stretch
Automated DNA Sequencer, Applied Biosys-
tems, Foster City, CA).
Web-Based Sequence Analysis Servers
The web-based sequence analysis servers used
were: http://gnomic.stanford.edu/GENSCAN.html
and http://www.sanger.ac.uk/Pfam/search.shtml.
Single-Strand Conformation Polymorphism
Analysis (SSCP)
Each exon of the kinase domain, plus a region
containing the proteolytic cleavage site in exon 1,
was examined for mutation using a specific PCR
primer pair (Table 1). The radioactive reaction was
performed in a total reaction volume of 12.5 ml,
containing 100 ng of genomic DNA, 12.5 pmol of
each primer, 200 mM dNTPs, 1.5 mM MgCl2, 1.25
nCi a35S-dATP, and 0.5 U AmpliTaq DNA poly-
merase (Perkin-Elmer). After heat denaturation (8
min at 90°C) in formamide buffer (Stop Solution,
Amersham, Arlington Heights, IL), PCR products
(ranging in size from 88 to 298 bp) were run over-
night in a 0.53 MDE gel (FMC Bioproducts,
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Rockland, ME), 0.63 TBE, at room temperature, 8
W constant power, transferred to 3 MM paper,
dried, and exposed for autoradiography on film
(X-OMAT AR, Kodak, Rochester, NY).
Patient DNA and Cell Lines
Fifty-five normal/tumor paired samples were an-
alyzed, including thirty-four small cell lung carci-
nomas (SCLCs) and twenty-one non-small cell
lung carcinomas (N-SCLCs). Tumor and lympho-
blastoid cell lines were established from patients
with lung cancer according to techniques previ-
ously described (Phelps et al., 1996). Tumor and
normal tissue were obtained from patients at sur-
gical resection or post-mortem examination (John-
son et al., 1988). The following DNA samples from
CEPH individuals were used as negative controls:
1334-01, 1334-02, 66-01, 66-02, 45-01, 45-02, 1331-
01, 1331-02, 1345-01, 1345-02, 28-01, 28-02, 21-01,
21-02, 1347-01, 1347-02, 1332-12, 1332-13, 1349-01,
1349-02, 1350-10, 1350-11, 1421-10, 1421-11, 1416-
10, 1416-11, 1346-01, 1346-02, 1400-01, 1400-02,
104-01, 104-02, 1355-01, 1355-02, 1427-01, 1427-02,
12-10, 12-11, 17-01, 17-02, 884-01, 884-02, 1420-10,
1420-11.
RON Cosmids
RON cosmid clones (designated numbers 5, 6, 11,
12, 19, and 20) were isolated by screening of a human
fetal brain genomic library in the SuperCos 1 vector
using the RON cDNA as a probe under conditions
specified by the vendor (Stratagene, La Jolla, CA).
The average insert size of these clones was estimated
to be between 35 and 45 kb.
Site-Directed Mutagenesis
T915C base change was introduced into RON
cDNA using the GeneEditor In Vitro Site-directed
Mutagenesis System (Promega, Madison, WI), ac-
cording to the manufacturer’s instructions. The
mutagenesis primer sequence was 59 P-CTA TCG
GGA GCC GGT CCT CG (GIBCO-BRL, Gaith-
ersburg, MD).
Cell Lines and Culture Conditions
MDCK cells (ATCC, Manassas, VA) were stably
transfected with wild-type or L296P RON cDNA in
pCl-neo vector (Promega, Madison, WI) or with
empty pCI-neo vector (MOCK) by superfect re-
agent (Quiagen, Santa Clara, CA), and placed in
medium with 500 mg/ml geneticin (GIBCO-BRL,
Gaithersburg, MD). After two weeks, the geneti-
cin-resistant cells were picked up and expanded
into cell lines. Expression of recombinant RON
was tested by Western blotting with anti-RON
antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA). Transfected MDCK cell lines were cultured
in DMEM (GIBCO-BRL) with 10% FCS (Hy-
Clone Lab, Logan, UT).
Cell Stimulation, Lysis, and Western Blotting
After overnight starvation in DMEM without
FCS, cells were collected from dishes and stimu-
lated in suspension with 5 nM MSP (Toyobo,
Osaka, Japan) for 15 min. After stimulation, cells
were lysed in lysis buffer (50 mM HEPES, pH 7.4,
150 mM NaCl, 10% glycerol, 1 mM EDTA, 1 mM
sodium orthovanadate, 10 mM sodium pyrophos-
phate, 100 mM NaF, 1% Triton X-100, 10 mg/ml
leupeptin, 10 U/ml aprotinin, 1 mM PMSF). Insol-
uble material was removed by centrifugation. RON
receptor was immunoprecipitated from superna-
tants using rabbit polyclonal antibodies designed
on the RON receptor C-terminus (Santa Cruz Bio-
technology). RON tyrosine phosphorylation was
detected by Western blotting using anti-phospho-
tyrosine antibodies (anti-PY, clone 4G10, UBI,
Lake Placid, NY). Rabbit anti-RON antibodies
were used for detection of RON receptor on the
membranes.
TABLE 1. PCR Primers Used for SSCP Analysis of the RON Gene Kinase Domain-Coding Exons
(exons 14–20) and Cleavage Site (exon 1)
PCR product Size in bp Forward primer Reverse primer
876F-971R 115 59TTAGCGCCACTGAGCCAGAGTTGG 59AGCACAGGGTAGGGCTGTCC
921F-1011R 112 59TCGACTGCAGATTTGCTCCA 59GTGGCAAGTTGGGCACCCACTG
EXON 14 159 59GCGGAAAGAGTCCATCCAG 59CTTGAGACTCCATCTCTGC
EXON 15 113 59ATTATGCACCTCACACCAGGCCAC 59CTGCCCCACTTACGACTTAGTGAC
EXON 16 206 59TCGCTCTGCAGGCATCACAGAGATG 59GATGAACACTGACCCGCTGAGGTGA
EXON 17 162 59TTGCCCACCAACCCACCTGTG 59CACCCCAGCTACTCTGGACTC
EXON 18 223 59AGTCCTAAGTGTGATCCTCTCCCTAC 59GCCTCACCACATCAGACTTGGTGGT
EXON 19 163 59CCACAGTGGTCATTTGGTGTGCTGC 59CCACCTCCACATACTCACAGAGAATCAG
EXON 20 108 59CAGGTACCAAGTGATGCAGCAATGCTG 59TCCCCAAGCAGTGCAGACACTATCTG
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RESULTS
RON Gene is Not Homozygously Deleted in Lung
Cancer Cell Lines
To investigate the retention of RON in the DNA
of lung cancer cell lines known to have homozy-
gous deletions in 3p21.3 (Wei et al., 1996), we
performed PCR with primers for exon 16 (Table 1).
We analyzed the lung cancer cell lines GLC 20,
NCI-H740, and NCI-H1450 that harbor the dele-
tions (Wei et al., 1996). The gene is not deleted in
any of the three tested cell lines (data not shown).
Expression Study in Lung Cancer Cell Lines
RON cDNA was used as a probe in Northern
blotting experiments. A panel of small and non-
small lung cancer cell lines showed high to moder-
ate expression of the 4.5 kb species in the majority
of samples (Fig. 1A upper arrow; 1B). In addition,
a signal of approximately 2 kb was detected in
small, but not in non-small cell lines (Fig. 1A, lower
arrow).
Characterization of the Exon-Intron Structure
Several PCR primer pairs were designed to cover
the whole RON cDNA sequence (GenBank acces-
sion number X70040). Comparison of PCR prod-
ucts generated from genomic DNA and RON
cDNA allowed detection of the position of intronic
sequences. In the case of large introns, we per-
formed direct primer-walking sequencing using
cosmid DNA. We identified a total of twenty exons
(Fig. 2). The first exon is also the largest, spanning
1229 bp. The last exon extends from nucleotide
3976 to 4532, where the polyA tail is inserted. Our
results confirm the existence of two previously re-
ported exons at bases 2678 and 2825 (Collesi et al.,
1996). With the exception of the first one, the
coding exons are small, ranging in size from 93 bp
to 253 bp (Table 2). The first, 14th, and 19th
introns were not completely sequenced. Intron 19
was estimated to be about 2.5 kb in size. The
whole gene cannot span more than about 35–45 kb,
because it is contained in a single cosmid clone
(data not shown). The intronic sequences were
deposited with the GenBank (accession numbers:
AF164633, AF164634, AF164635, AF164636,
AF164637, AF164638, AF164639, AF164640,
AF164641, AF164642, AF164643, AF164644,
AF164645, AF164646, AF164647, AF164648,
AF164649, AF164650, AF164651, AF164652,
AF164653, AF164654).
By using the GENSCAN gene prediction program
(Burge and Karlin, 1997; http://gnomic.stanford.edu/
GENSCAN.html), we checked whether any alterna-
tive splicing could be detected. We found that exon
10 could begin with a CAG triplet (coding for a Gln
residue) upstream of the canonical TGT (coding for
the canonical Cys) without modifying the consensus
splicing site sequence 59…nCAG39. Another interest-
ing possibility was found at residue 1091, where, after
the canonical VIGKG sequence, the theoretical alter-
native splicing inserts a stretch of bases encoding 6
more amino acids (namely, VGARPG). This last pos-
sibility occurs at the very beginning of the kinase
domain. A PCR experiment was performed with
cDNAs from human fetal and adult lung (Clon-
tech, Palo Alto, CA) to search for the predicted
alternatively spliced forms of RON. This experi-
ment gave negative results (data not shown). It is
worth mentioning, however, that inactivating mu-
tations responsible for disease states caused by the
Wilms’ tumor suppressor gene (WT1) occur in
amino acid residues subjected to alternative splic-
ing (Hewitt et al., 1996).
Mutation Analysis
With a panel of primers (Table 1), we performed
SSCP analysis of a stretch of bases in exon 1,
encoding the putative cleavage site (KRRRR) in
the RON protein, to verify whether any mutation
at this site could interfere with correct maturation
of the protein. We also analyzed exons 14, 15, 16,
17, 18, 19, and part of 20, that encode the tyrosine
Figure 1. Northern blot analysis. RON complete cDNA was used as
probe in Northern blot experiments. (A) poly-A1 mRNA from small-
cell lung cancer cell lines. (B) poly-A1 mRNA from non-small cell lung
cancer cell lines. The arrow in B and the upper arrow in A point to a
4.5 kb transcript. A smaller transcript was found in small-cell lung
cancer cell lines (2 kb, lower arrow in blot A).
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kinase domain (PFAM: Bateman et al., 1999; http://
www.sanger.ac.uk/Pfam/search.shtml).
A T-to-C transition was found at base 915 (tat
cgg gag ct/cg gtc ctc) in the tumor DNA of an
adenocarcinoma patient (Patient 122-208). This
base change causes an L-to-P change at residue 296
(Fig. 3A) and is present neither in the blood-de-
rived DNA of the patient (Fig. 3A) nor in 44 con-
trol individuals (CEPH individuals’ DNA; Dausset
et al., 1990). The mutation eliminates an AluI site
and allows the formation of a Cfr10I restriction site,
which cuts the PCR product amplified by primers
876F-917R (Table 1) in two fragments of 38 and 77
bp. A change was found at base 993: an A-to-G
transition leads to a Q322R amino-acid change
(Fig. 3B). This is a single nucleotide polymorphism
(SNP), already observed by Collesi et al., (1996). It
is present in the normal population with an index
of heterozygosity of 0.28 (P 5 0.17, q 5 0.83). This
SNP cancels a BspMI restriction site in the PCR
product of primers 921F-1011R (Table 1), other-
wise cut into two fragments of 31 and 71 bp. In
exon 20, two SNPs were found (Fig. 3C, 3D): a
C-to-T transition of base 4024 (gtg cga ccc/t acc ttc
aga; same-sense variant P1341P) and an A-to-G
transition of base 4031 (ccc acc ttc a/gga gta:
R1344G). Both SNPs were found in CEPH indi-
viduals’ DNA (Dausset et al., 1990), with indices of
heterozygosity, respectively, of 0.03 and 0.46.
These SNPs do not produce any change in the
restriction map.
Protein Analysis
Because the T915C mutation was found only in
a tumor sample, we investigated the kinase activity
of the L296P RON mutant. To compare the mu-
tant protein with wild-type RON, we introduced
the T915C base change into RON cDNA, through
a site-specific mutagenesis procedure. MDCK cells
stably transfected with C915T-mutagenized RON
cDNA express RON protein that shows the same
electrophoretic profile as the wild-type protein
(Fig. 4A). Therefore, the mutation, although close
to the cleavage site, does not block the precursor
cleavage and protein maturation. The mutated pro-
tein is responsive to MSP, and the kinase activity,
elicited upon MSP stimulation, is equivalent to the
wild-type activity (Fig. 4B).
DISCUSSION
We established the exon/intron structure of the
human RON gene. The coding sequence is repre-
sented by twenty exons. Ranging in size from 93–
253 bp, they all are quite small, a feature shared
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with other receptor tyrosine kinases (Andre et al.,
1992; Kwok et al., 1993; Duh et al., 1997). All
intronic splice junction sites show the consensus
sequence 59 GT (x)n AG 39 (Mount, 1982). Exclud-
ing the three largest ones, the intronic sequences
have an average size of 205 bp, ranging from 79–
545 bp in length.
There is quite a remarkable conservation of the
exon-intron organization of the human RON gene
and its mouse ortholog, Stk (Waltz et al., 1998). The
intervening sequences are of the same type (as
classified by Sharp, 1981) and in the same place,
with the exception of the human exon 13, which,
along with the adjacent intron 13, is not present in
the mouse gene. Similarly to the mouse Stk gene
(Waltz et al., 1998), the first exon is the largest and
codes for the putative proteolytic cleavage site
KRRRR. The PFAM (http://www.sanger.ac.uk/
Pfam/search.shtml) protein domains alignment
program detected a SEMA domain, located in the
first, second, and third exons of the RON gene
(corresponding to amino acid residues 58–507).
The SEMA domain consists of a highly conserved
stretch of about 500 amino acids (Kolodkin et al.,
1993), initially identified in the Semaphorin family
of proteins. It is characterized by fifteen conserved
cysteines, one conserved potential N-linked glyco-
sylation site, and several blocks of conserved resi-
dues throughout the domain (Kolodkin et al.,
1993). Besides the RON and MET receptor ty-
rosine kinases (human and orthologs), PFAM re-
trieves the SEMA domain in Semaphorins, Neuro-
pilins, and the orphan receptors of the SEX family
(Maestrini et al., 1996), expressed in neural and
epithelial cells. Unlike the RON/MET family, the
SEX family proteins do not have any kinase activ-
ity.
Although the role of the SEMA domain is not
clarified, it was shown that it could function in
homophilic binding in the presence of calcium ions
(Ohta et al., 1995). We propose that, owing to its
location in RON and MET, the SEMA domain
could be involved in ligand binding and receptor
homodimerization upon ligand stimulation. Studies
are ongoing to investigate the functional role of the
SEMA domain in RON. Other structural features
are located as follows (Fig. 2): a plexin domain
(http://www.sanger.ac.uk/Pfam/search.shtml) in
exon 4; three IPT domains (Bork et al., 1999)
Figure 3. Mutation analysis. The SSCP profile of each base change is
shown, along with the sequence. A dot marks the mutated base. (A)
T915C: L296P mutation. T: DNA from a lung adenocarcinoma sample.
The arrow points to the mutated base found in this sample. The
mutation affects the SEMA domain. N: blood-derived DNA from the
same patient. (B) A993G; Q322R SNP. This polymorphism occurs in
the SEMA domain. SNPs occurring in exon 20: (C) C4024T:P1341P, (D)
A4031G:R1344G.
TABLE 2. Data on Exons and Introns of the Human RON Gene
Exon no.
(length in bp) Endsa
Intron
no. Typeb Intron 59 endc
Length
in bp Intron 39 endc
1 (1229) ATG 29–1258 1 0 CCCAACCCG(1258)/gtaagctga ND ctttcccag/(1259)CCTGGCCTG
2 (188) 1259–1447 2 0 TATCCTGCAG/gtgggtcctc 79 cctgtcctag/GTGGAGCTGG
3 (128) 1448–1576 3 0 TGGGGACCAG/gtgaggtggg 178 tcacccacag/GTTTTCCAGG
4 (170) 1577–1747 4 0 GCTTACTGAG/gtatggcttc 306 cccatttcag/TTCCACCCCC
5 (160) 1748–1908 5 II CAAAACTCAG/gtacaatctg 365 tggtgccccag/ACCAGTGCCC
6 (165) 1909–2074 6 0 CTCTTTCATG/gtgaggctac 103 gtcctcttag/GAGCCAGTGC
7 (136) 2075–2211 7 II TGCTAGCACG/gtaagtacca 385 gttcctgtag/GGTCAGTGAG
8 (162) 2212–2374 8 II GTGGCTACAT/gtaagcactg 95 tcttccacag/CAACTCCCAC
9 (93) 2375–2468 9 0 GGAAAGCAGG/gtgagtgagt 135 gtcccagcag/TGTGAGAGGC
10 (208) 2469–2677 10 0 TAAGTTTGAG/gtaagtgtaa 86 ctctctgcag/TATATTGGGC
11 (146) 2678–2824 11 0 CCCATTGCAG/gtaggcagcc 80 ctgcccccag/GTCTGCGTAG
12 (165) 2825–2990 12 I AAGCAGCTAG/gtgagttctc 166 ctttccacag/TTCTTCCTCC
13 (101) 2991–3092 13 I AGTGGCCTTG/gtgagatagt 72 ttccccacag/CACTCCCTGC
14 (207) 3093–3300 14 I ATTGGCAAAG/gtgtgggggc ND ctcagaccag/GCCACTTTGG
15 (80) 3301–3381 15 I TCACTAAGTC/gtaagtgggg 175 cgctctgcag/GCATCACAGA
16 (182) 3382–3564 16 0 ACCTCAGCGG/gtcagtgttc 92 gtgcccccag/AACCCCACCG
17 (109) 3565–3674 17 II GGAACTGCAT/gtgagagtcc 545 tacccctaag/GCTGGACGAG
18 (165) 3675–3840 18 0 GTCTGATGTG/gtgaggcccc 423 ctttccacag/TGGTCATTTG
19 (136) 3841–3977 19 II CTGATTCTCT/gtgagtatgt ND cccccaacag/GTACCAAGTG
20 (556) 3978–4534
aFour-digit numbers refer to RON cDNA sequence (GenBank acc. No. X70040).
bAs classified in Sharp (1981).
cCapital letters represent exonic sequence.
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Figure 3.
distributed in exons 4–10; a putative transmem-
brane domain in exon 12; the tyrosine kinase do-
main in exons 14–20; two conserved, adjacent ty-
rosine residues, that should serve as putative major
autophosphorylation sites in exon 18; and the SH2
binding site (Ponzetto et al., 1994; Zhen et al.,
1994) in exon 20.
The hypothesis of RON involvement in lung
cancer was tested by mutation analysis of the ki-
nase domain (exons 14–20), because evidence ex-
ists that oncogenic mutations found in the MET
kinase domain, when introduced into RON, are
able to activate its oncogenic potential (Santoro et
al., 1998). We also analyzed the region containing
the cleavage site in exon 1, to check for mutation
that could possibly interfere with the cleavage/
maturation process. Using the SSCP protocol fol-
lowed by sequencing, we identified a C-to-T tran-
sition at base 915 (leading to L296P mutation) in
the tumor DNA of an adenocarcinoma patient.
Leu296 is conserved among human, mouse, and
Xenopus RON orthologues. It is substituted by Ile,
a very similar amino acid, in the chicken homo-
logue, c-SEA. Despite this conservation, however,
the mutated amino acid does not seem to play a
fundamental role, because the substitution L296P
does not change the protein cleavage and matura-
tion (as deduced by the electrophoretic profile) and
the ligand-induced phosphorylation status, and
therefore, most likely, the overall protein function.
Thus, from our mutation analysis in lung cancer
samples, we can rule out the possibility that RON
plays a causative role in lung cancer initiation, at
least with a mechanism involving mutations of the
kinase domain or the cleavage site in exon 1. Sev-
eral polymorphisms were found: A993G:Q322R
(confirming the observation of Collesi et al., 1996);
C4024T:same-sense variant; and A4031G:R1344G.
While this manuscript was in preparation, Per-
sons et al. (1999) reported that the FV2 locus,
which confers susceptibility to the Friend erythro-
leukemia virus in mice, encodes a truncated form
of Stk, the mouse ortholog of RON (Waltz et al.,
1998). Noticeably, the Northern analysis of small-
cell lung cancer cell lines (Fig. 1A) showed a
smaller (about 2 kb) transcript of RON, present in
all samples, whereas the normal-size transcript was
absent in some. This circa 2 kb transcript was not
present at all in the non-small cell lines (Fig. 1 B),
that expressed only the normal (4.5 kb) transcript.
We are in the process of studying the nature and
possible role of this smaller transcript in small cell
lung cancer. In fact, a transcript approximately 2 kb
in size was reported by others in some normal
tissues (Ronsin et al., 1993; Gaudino et al., 1994),
but the nature, function, and possible significance
of this molecule in human physiology and pathol-
ogy remain unknown at present.
In conclusion, further research is required to
discover human tumors in which RON mutations
Figure 4. Analysis of the mutant RON protein. MDCK cells stably
expressing wild-type RON (WT) or L296P mutant were stimulated
with MSP (see Materials and Methods), and then lysed. RON was
immunoprecipitated from cell lysates. Parental MDCK cells transfected
with empty vector (MOCK) were used as a negative control. (A)
Immature (upper band) and mature (lower band) forms of RON. This
blot, developed with anti-RON antibodies, serves also as a control for
the amount of RON in precipitates. (B) RON tyrosine phosphorylation
was detected by Western blotting with anti-phosphotyrosine (PY)
antibodies.
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may play a causative role. The panel of primers
developed in this study is a useful tool for further
mutation analyses in human malignancies.
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